RNA interference against hepatic epidermal growth factor receptor has suppressive effects on liver regeneration in rats.
Liver regeneration after a two-thirds partial hepatectomy (PHx) is a complex process requiring interaction and cooperation of many growth factors and cytokines and cross talk between multiple pathways. Along with hepatocyte growth factor and its receptor MET (HGF-MET), the epidermal growth factor receptor (EGFR) signaling pathway is activated within 60 minutes after PHx. To investigate the role of EGFR in liver regeneration, we used two EGFR-specific short hairpin silencing RNAs to inhibit EGFR expression in regenerating normal rat liver. Suppression of EGFR mRNA and protein was evident in treated rats. There was also a demonstrable decrease but not complete elimination of bromo-deoxyuridine incorporation and mitoses at 24 hours after PHx. In addition, we observed up-regulation of MET and Src as well as activation of the ErbB-3-ErbB-2-PI3K-Akt pathway and down-regulation of STAT 3, cyclin D1, cyclin E1, p21, and C/EBP beta. The decrease in the ratio of C/EBP alpha to C/EBP beta known to occur after PHx was offset in shEGFR-treated rats. Despite suppression of hepatocyte proliferation lasting into day 3 after PHx, liver weight restoration occurred. Interestingly, hepatocytes in shEGFR-treated rats were considerably larger when compared with ScrRNA-treated controls. The data indicate that although the MET and EGFR pathways are similar, the contributions made by MET and EGFR are unique and are not compensated by each other or other cytokines.
Paranjpe
Shirish
S
Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Bowen
William C
WC
Tseng
George C
GC
Luo
Jian-Hua
JH
Orr
Anne
A
Michalopoulos
George K
GK
D000818:Animals; D049109:Cell Proliferation; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism*; D020869:Gene Expression Profiling; D006498:Hepatectomy; D008099:Liver / Q000502:physiology*; D008115:Liver Regeneration / Q000502:physiology*; D008297:Male; D046228:Microarray Analysis; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics / Q000378:metabolism; D034622:RNA Interference; D051381:Rats; D011916:Rats, Inbred F344; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D020893:Receptor, ErbB-3 / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
D066246:ErbB Receptors; D019869:Phosphatidylinositol 3-Kinases; D019859:Proto-Oncogene Proteins c-met; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3
Exp Cell Res. 2003 Mar 10;284(1):78-88
12648467
J Gastroenterol Hepatol. 1991 Nov-Dec;6(6):615-24
1782378
Gastroenterology. 2002 Dec;123(6):2017-27
12454858
Hepatology. 2008 Dec;48(6):1932-41
18846549
Mol Cell Biol. 1994 Jun;14(6):3550-8
7515147
FASEB J. 2006 Aug;20(10):1611-21
16873884
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93
15731348
Am J Respir Cell Mol Biol. 2005 Nov;33(5):490-9
16055672
Nature. 1995 Jul 27;376(6538):337-41
7630400
Biochem Biophys Res Commun. 2002 Jan 11;290(1):197-203
11779153
Dev Biol. 2009 Mar 1;327(1):177-90
19133254
Trends Mol Med. 2007 Dec;13(12):527-34
17981505
Mol Cancer Ther. 2005 Apr;4(4):650-8
15827339
Genes Dev. 1996 Feb 1;10(3):245-60
8595876
J Hepatol. 2005 Nov;43(5):799-807
16083985
Ciba Found Symp. 1977;(55):95-107
306914
Cancer Res. 2006 Mar 1;66(5):2544-52
16510571
Lab Invest. 1989 Jan;60(1):4-13
2642989
Breast Cancer Res Treat. 2006 Jan;95(1):17-27
16267617
Hepatology. 1995 Jun;21(6):1695-701
7768515
Hepatology. 2006 Jul;44(1):164-73
16799991
Science. 1997 Apr 4;276(5309):60-6
9082986
Cancer Res. 1996 Aug 15;56(16):3666-9
8706005
Placenta. 2007 Nov-Dec;28(11-12):1211-8
17822758
Hepatology. 1998 Sep;28(3):707-16
9731563
Hepatology. 2006 Feb;43(2 Suppl 1):S45-53
16447274
Gastroenterology. 2005 Feb;128(2):424-32
15685553
Am J Physiol. 1999 Nov;277(5):G917-21
10564095
Clin Cancer Res. 2005 Dec 1;11(23):8288-94
16322287
Nat Rev Cancer. 2009 Jul;9(7):463-75
19536107
J Surg Res. 2006 Dec;136(2):227-31
17059835
Cancer Res. 2002 Feb 15;62(4):995-9
11861371
J Hepatol. 2008 Feb;48(2):237-45
18068850
Proc Natl Acad Sci U S A. 2003 May 27;100(11):6347-52
12746500
Hepatology. 2007 Jun;45(6):1471-7
17427161
J Cell Physiol. 2007 Nov;213(2):286-300
17559071
Br J Cancer. 2009 Mar 24;100(6):941-9
19240716
Gastroenterology. 2009 Aug;137(2):691-703, 703.e1-6
19445941
Gastroenterology. 2005 Feb;128(2):503-6
15685562
Mech Dev. 1999 Apr;82(1-2):3-21
10354467
J Biol Chem. 2005 Jan 28;280(4):2562-8
15536070
Mol Carcinog. 1997 Apr;18(4):244-55
9142219
J Cell Biochem. 2007 Oct 1;102(2):311-9
17661350
Mol Cell Biol. 2005 Sep;25(17):7432-40
16107692
J Biol Chem. 1994 May 20;269(20):14661-5
7514177
Hepatology. 2001 Apr;33(4):848-59
11283849
Oncogene. 2008 Jun 26;27(28):3944-56
18297114
Cancer Res. 2008 May 1;68(9):3314-22
18451158
J Biol Chem. 2000 Mar 24;275(12):8806-11
10722725
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
Hepatology. 2009 Jan;49(1):204-14
19065678
Nature. 2007 Jan 25;445(7126):437-41
17206155
J Biol Chem. 2003 Apr 4;278(14):12055-63
12556529
Cancer Res. 2009 Oct 1;69(19):7587-94
19738054
Invest Ophthalmol Vis Sci. 2007 May;48(5):2242-8
17460286
Nat Rev Cancer. 2004 Feb;4(2):97-105
14964307
J Clin Invest. 1995 Sep;96(3):1351-65
7657810
Methods. 2001 Dec;25(4):402-8
11846609
Gene Expr. 2003;11(2):55-75
12837037
J Mol Biol. 1981 Mar 25;147(1):195-7
7265238
Am J Pathol. 2001 Feb;158(2):771-7
11159214
Oncogene. 2007 May 24;26(24):3503-10
17173075
J Clin Oncol. 2008 Apr 10;26(11):1836-42
18398149
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17081-6
17940036
Trends Cell Biol. 2006 Dec;16(12):649-56
17085050
Differentiation. 2007 Nov;75(9):770-87
17999740
Science. 2007 May 18;316(5827):1039-43
17463250
Cancer Res. 2006 Apr 1;66(7):3603-10
16585185
Mol Cancer Res. 2007 Apr;5(4):393-401
17426253
Cancer Res. 1999 Aug 15;59(16):3954-60
10463591